Pharmacological principles of antibiotic prescription in the critically III

Anaesthesia and Intensive Care

Volumn 30, Issue 2, 2002, Pages 134-144

  Pinder, M ^a   Bellomo, R ^a   Lipman, J ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Acute renal failure; Antibiotics; Haemofiltration; Intensive care unit; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; CREATININE; GLYCOPEPTIDE; IMIPENEM; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERUM ALBUMIN; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; FLUID SHIFT; HEART OUTPUT; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER DISEASE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PATHOGENESIS; PRESCRIPTION; REVIEW; SEPSIS;

EID: 0036229241     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0203000203     Document Type: Review

References (110)

1. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
2. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
3. The pharmacodynamics of beta-lactams
4. Subtleties of antibiotic dosages-do doses and intervals make a difference in the critically ill?
5. The importance of antibiotic pharmacokinetics in critical illness
6. Kinetics of antimicrobial activity
7. Altered pharmacokinetics of ceftazidime in critically ill patients
8. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing
9. Low cefpirome levels during twice daily dosing in critically ill septic patients: Pharmacokinetic modelling calls for more frequent dosing
10. Changes in vancomycin pharmacokinetics in critically ill infants
11. Generalized vascular permeability and pulmonary function in patients following serious trauma
12. Whole-body inflammation in trauma patients. An autopsy study
13. Pathogenetic mechanisms of septic shock
14. Postantibiotic effects
15. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats
16. Impact of dosage schedule of antibiotics on the treatment of serious infections
17. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients
18. Role for dual individualization with cefmenoxime
19. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
20. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits
21. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach
22. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
23. Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives
24. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess
25. Aminoglycoside ototoxicity: Influence of dosage regimen on drug uptake, correlation between membrane binding and clinical features
26. Once daily aminoglycoside dosing: Maintained efficacy with reduced nephrotoxicity?
27. Therapeutic monitoring of aminoglycoside antibiotics: An approach
28. Aminoglycoside pharmacokinetics: Volume of distribution in specific adult patient subgroups
29. Gentamicin dosage requirements: Wide interpatient variations in 242 surgery patients with normal renal function
30. Altered aminoglycoside pharmacokinetics in the critically ill
31. Gentamicin volume of distribution in critically ill septic patients
32. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients
33. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients
34. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients
35. Aminoglycoside pharmacokinetics: Dosage requirements and nephrotoxicity in trauma patients
36. Inadequacy of standard aminoglycoside loading doses in acutely ill patients
37. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients
38. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis
39. Aminoglycoside volume of distribution and illness severity in critically ill septic patients
40. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
41. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
42. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review
43. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
44. Alternative dosing strategy for aminoglycosides: Impact on efficacy, nephrotoxicity, and ototoxicity
45. Once-daily aminoglycoside therapy
46. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: Comparison of once- versus twice-daily dosing regimens
47. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients
48. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection
49. Once versus thrice daily gentamicin in patients with serious infections
50. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
51. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration
52. Tobramycin clearance during simulated continuous arteriovenous hemodialysis
53. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model
54. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa
55. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
56. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion
57. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
58. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
59. Pharmacokinetics and pharmacoeconomic evaluation of ticarcillin-clavulanate administered as either continuous or intermittent infusion with once-daily gentamicin
60. Continuous infusion of beta-lactam antibiotics
61. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia
62. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia
63. Intermittent and continuous ceftazidime infusion for critically ill trauma patients
64. Dosage adjustment for ceftazidime in patients with impaired renal function
65. Pharmacokinetics of antibiotics in critically ill patients
66. The pharmacokinetics of prophylactic antibiotics in trauma
67. Aminoglycoside dosing in burn patients using first-dose pharmacokinetics
68. Intermittent bolus dosing of ceftazidime in critically ill patients
69. Continuous infusion ceftazidime in intensive care: A randomized controlled trial
70. Drug Administration in Intermittent Renal Replacement
71. Drug Use in Critically Ill Patients with Acute Renal Failure
72. Comparative pharmacokinetics of the carbapenems: Clinical implications
73. Continuous infusion versus intermittent administration of meropenem in critically ill patients
74. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model
75. Meropenem: A review of its use in patients in intensive care
76. Antibiotic infusions reduce the incidence of resistant organisms in liver intensive care
77. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration
78. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration
79. Vancomycin administration and monitoring reappraisal
80. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response
81. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions
82. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections
83. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection
84. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis
85. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study
86. Should quinolones be used in the treatment of bacterial infections in neutropenic patients?
87. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
88. Dosing considerations with intravenous ciprofloxacin in critical care patients
89. Questioning dosing regimens of ciprofloxacin
90. Post-antibiotic suppressive effect of ciprofloxacin against gram- positive and gram-negative bacteria
91. Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously
92. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
93. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses
94. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime
95. The selection of appropriate dosages for intravenous ciprofloxacin
96. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens
97. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa
98. Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations
99. AHFS Drug information
100. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis
101. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
102. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies
103. Guidelines for Drug Dosing during Continuous Renal Replacement Therapies
104. Drug administration in critically ill patients with acute renal failure
105. A comparison of solute clearance during continuous hemofiltration, hemodiafiltration, and hemodialysis using a polysulfone hemofilter
106. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock
107. Microdialysis. A novel tool for clinical studies of anti-infective agents